statement

The cancellation price for each Frontage Holdings share is HK$2.37, a 107.2% premium to the average share price over the past 360 days, equivalent to about 91.6 times Frontage's 2025 price-to-earnings ratio.

A statement by 瑞銀. Statements are as reported by the cited publishers — not verified by DecisionGateway.

方達控股每股註銷價為2.37港元,較過去360日平均股價溢價107.2%,相當於方達控股2025年市盈率約91.6倍。
stockintelligencenewsPublished 2026-11-11 Read source

Discussion

0/2000

Related claims

The cancellation price per Frontage Holdings share is HK$2.37, a 107.2% premium to the 360-day average share price, equivalent to about 91.6 times Frontage's 2025 price-to-earnings ratio.瑞銀 · statementAlthough divesting Frontage may affect some global synergies in the short term, the transaction can improve Tigermed's business portfolio and capital allocation while supporting further expansion of overseas clinical CRO business, supplementing working capital and raising shareholder returns.瑞銀 · predictionAfter the privatization is completed, Tigermed plans to acquire Frontage's non-target business in mainland China at a preliminary valuation of about US$205.5 million; the target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; Frontage founder Li Song and related trusts may acquire the overseas non-target business at a preliminary valuation of about US$84.4 million.瑞銀 · statementAfter the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses at a preliminary valuation of about US$205.5 million; target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; founder Li Song and related trusts may acquire the overseas non-target businesses at a preliminary valuation of about US$84.4 million.瑞銀 · statementTigermed announced it will participate in the privatization and business split of Frontage Holdings (01521) through its wholly-owned subsidiary Hong Kong Tigermed.瑞銀 · statementFrontage Holdings' laboratory network in the US and Europe is an important platform linking Tigermed to global markets; it supports the strategy of dual IND submissions in China and the US and helps Chinese innovative drugmakers expand into overseas markets.瑞銀 · statement

More claims by 瑞銀

All claims by 瑞銀